[Fundamental and clinical studies on ceftazidime].
Ceftazidime ( CAZ ) was evaluated for its pharmacokinetics and clinical effects in the treatment of obstetrical and gynecological infections. The following results were obtained: Transfer of CAZ into various parts in the uterus and the uterine adnexa was found to be satisfactory, and relatively high concentration of the drug was maintained in the pelvic dead space exudate. Infections in the obstetrics and gynecology: 2 approximately 4 g of CAZ was given to 12 patients for 4 approximately 11 days and satisfactory clinical effect was obtained in 9 patients. There was a slight GOT elevation in 1 case but no other appreciable side effect or abnormal laboratory value was observed.
D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D002442:Ceftazidime; D002511:Cephalosporins / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D004341:Drug Evaluation; D005122:Exudates and Transudates / Q000378:metabolism; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D005836:Genitalia, Female / Q000378:metabolism*; D006801:Humans; D010388:Pelvis
D002511:Cephalosporins; D002442:Ceftazidime